Cashin Richard M Jr 的 Form 4/A 修正申報
修正AdaptHealth Corp.（AHCO），2026/3/30 申報
- 申報編號
- 0001193125-26-132703
- 申報時間
- 2026/3/30 19:49 ET
- 交易日
- 2026/3/19-3/20
- 申報延遲
- 11 天
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2026/3/23
這份申報列了 2 筆非衍生性交易。沿用原件裡沒有重述的 3 筆交易。公開市場買進合計 $2,435 萬。交易後 11 天申報。
這份修正申報重述了 0001193125-26-132663（2026/3/30 申報）的一部分，沒有重述的交易仍然有效，列在下面。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Cashin Richard M JrCIK 0001172898 | 持股 10% 以上大股東 |
| One Equity Partners VII, L.P.CIK 0001733523 | 持股 10% 以上大股東 |
| One Equity Partners VII-A, L.P.CIK 0001733525 | 持股 10% 以上大股東 |
| One Equity Partners VII-B, L.P.CIK 0001733528 | 持股 10% 以上大股東 |
| OEP AHCO Investment Holdings, LLCCIK 0001817112 | 持股 10% 以上大股東 |
| OEP VII General Partner, L.P.CIK 0001817115 | 持股 10% 以上大股東 |
| Oep VII GP, L.L.C.CIK 0001817118 | 持股 10% 以上大股東 |
| OEP VII Project A Co-Investment Partners, L.P.CIK 0001817120 | 持股 10% 以上大股東 |
| Oep VII Project A-I Co-Investment Partners, L.P.CIK 0001821208 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效，網站的交易表把它們算在這份修正申報底下。
來自 0001193125-26-132663（2026/3/30 申報）。
非衍生性證券（表 I）
原件的附註
這幾筆交易的價格在原件上引用的附註。
- F1
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.58 to $9.95, inclusive. The reporting persons undertake to provide to AdaptHealth Corp., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.64 to $9.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.55 to $9.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.94 to $9.95, inclusive. The reporting persons undertake to provide to AdaptHealth Corp., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F2
These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").
- F3
(Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.
- F4
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.81 to $9.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
備註
This filing is being amended solely to reflect Investor, the Parallel Funds, OEP VII GP, OEP VII GP LLC (collectively, the "OEP Entities") as reporting persons and direct and indirect holders of the reported securities, which were previously reported on a Form 4 that was timely filed by Richard Cashin on March 23, 2026 (the "Original Form 4 Filing"). As noted in the remarks, the Original Form 4 Filing disclosed the OEP Entities' direct and indirect ownership and noted that Edgar filing codes were not available at such time but that the Original Form 4 Filing would be amended once such codes became available.